CN112789059A - 氨基酸类营养素的应用以及包含它的药物组合物 - Google Patents

氨基酸类营养素的应用以及包含它的药物组合物 Download PDF

Info

Publication number
CN112789059A
CN112789059A CN201980056356.8A CN201980056356A CN112789059A CN 112789059 A CN112789059 A CN 112789059A CN 201980056356 A CN201980056356 A CN 201980056356A CN 112789059 A CN112789059 A CN 112789059A
Authority
CN
China
Prior art keywords
tumor
amino acid
pharmaceutical composition
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056356.8A
Other languages
English (en)
Inventor
邹方霖
邹礼常
王建霞
王艺羲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Kuachang Aopu Medical Technology Co ltd
Original Assignee
Chengdu Kuachang Aopu Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kuachang Aopu Medical Technology Co ltd filed Critical Chengdu Kuachang Aopu Medical Technology Co ltd
Publication of CN112789059A publication Critical patent/CN112789059A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种包含高浓度氨基酸类营养素及其协同物的药物组合物和包含该组合物的装置，及该组合物在制备治疗局部病变疾病的药物组合物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980056356.8A 2018-08-31 2019-08-30 氨基酸类营养素的应用以及包含它的药物组合物 Pending CN112789059A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110096988 2018-08-31
CN201811009698.8A CN110870914A (zh) 2018-08-31 2018-08-31 氨基酸类营养素的应用以及包含它的药物组合物
PCT/CN2019/103659 WO2020043185A1 (zh) 2018-08-31 2019-08-30 氨基酸类营养素的应用以及包含它的药物组合物

Publications (1)

Publication Number Publication Date
CN112789059A true CN112789059A (zh) 2021-05-11

Family

ID=69643968

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811009698.8A Pending CN110870914A (zh) 2018-08-31 2018-08-31 氨基酸类营养素的应用以及包含它的药物组合物
CN201980056356.8A Pending CN112789059A (zh) 2018-08-31 2019-08-30 氨基酸类营养素的应用以及包含它的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811009698.8A Pending CN110870914A (zh) 2018-08-31 2018-08-31 氨基酸类营养素的应用以及包含它的药物组合物

Country Status (6)

Country Link
US (1) US20220151935A1 (zh)
EP (1) EP3845247A4 (zh)
JP (1) JP2021536502A (zh)
KR (1) KR20210055052A (zh)
CN (2) CN110870914A (zh)
WO (1) WO2020043185A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110870868A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用
CN110870860A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含氨基酸类营养素和常规无效化合物的药物组合物及其应用
CN109846046A (zh) * 2019-04-10 2019-06-07 山东汉泰生物科技有限公司 一种提高免疫力的甘露糖-氨基酸复合物
WO2021163897A1 (zh) * 2020-02-18 2021-08-26 成都夸常奥普医疗科技有限公司 包含亚甲蓝类染料、营养素或/和常规抗肿瘤药的药物组合物及其应用
WO2021164706A1 (zh) * 2020-02-18 2021-08-26 成都夸常奥普医疗科技有限公司 包含亚甲蓝类染料的药物组合物及其应用
JP2023544310A (ja) * 2020-09-30 2023-10-23 チェンドゥ クァチャンアオプー メディカル テクノロジー カンパニー リミテッド プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物
CA3216616A1 (en) * 2021-04-27 2022-11-03 Philip V. Felice Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use
WO2023130205A1 (zh) * 2022-01-04 2023-07-13 成都夸常奥普医疗科技有限公司 一种稳定溶液、制备方法、应用、药物组合物及试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690967A (en) * 1986-12-23 1997-11-25 Tristrata Technology, Inc. Compositions for improved topical delivery of lactic acid
CN1336817A (zh) * 1999-01-08 2002-02-20 瑞·J·余 含n－乙酰基－醛糖胺或n－乙酰基氨基酸的局部用组合物
CN1846676A (zh) * 2006-01-18 2006-10-18 济南帅华医药科技有限公司 含氟尿嘧啶增效剂的缓释注射剂及其制备方法
CN101223999A (zh) * 2008-01-21 2008-07-23 成都自豪药业有限公司 一种全面补充各种人体所需的营养素组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234122B (zh) * 2008-03-03 2010-06-30 中国科学院化学研究所 多聚赖氨酸的新用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690967A (en) * 1986-12-23 1997-11-25 Tristrata Technology, Inc. Compositions for improved topical delivery of lactic acid
CN1336817A (zh) * 1999-01-08 2002-02-20 瑞·J·余 含n－乙酰基－醛糖胺或n－乙酰基氨基酸的局部用组合物
CN1846676A (zh) * 2006-01-18 2006-10-18 济南帅华医药科技有限公司 含氟尿嘧啶增效剂的缓释注射剂及其制备方法
CN101223999A (zh) * 2008-01-21 2008-07-23 成都自豪药业有限公司 一种全面补充各种人体所需的营养素组合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EMAD Y. MOAWAD: "Administering the Optimum Dose of L-Arginine in Regional Tumor Therapy", 《INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY》 *
周雪峰，等: "谷氨酰胺和5-氟尿嘧啶对荷瘤大鼠肿瘤生长的影响", 《现代医药卫生》 *
尹晓燕，等: "5-氟尿嘧啶联合L-精氨酸治疗裸鼠人肝癌移植瘤的研究", 《中国药理学通报》 *
李宾，等: "精氨酸及其产物在消化道肿瘤中的作用", 《新医学》 *
查文良，等: "不平衡氨基酸肠内营养联合5-氟尿嘧啶对大鼠Walker-256癌肉瘤生长的影响", 《实用医学杂志》 *
石晓蕾: "门冬氨酸鸟氨酸联合乳果糖治疗酒精性肝病高氨血症的临床疗效", 《临床医学》 *

Also Published As

Publication number Publication date
EP3845247A1 (en) 2021-07-07
JP2021536502A (ja) 2021-12-27
CN110870914A (zh) 2020-03-10
US20220151935A1 (en) 2022-05-19
KR20210055052A (ko) 2021-05-14
WO2020043185A1 (zh) 2020-03-05
EP3845247A4 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
CN112789059A (zh) 氨基酸类营养素的应用以及包含它的药物组合物
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
CN110870868A (zh) 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用
WO2002096406A1 (fr) Compositions medicinales
CN110870869A (zh) 包含糖类营养素和常规无效化合物的药物组合物及其应用
CN102579341A (zh) 一种多西他赛固体脂质纳米粒及其制备方法
CN116747233A (zh) 包含5-胆甾烯-3,25-二醇,3-硫酸酯或其盐和至少一种环状寡糖的组合物
WO2021164706A1 (zh) 包含亚甲蓝类染料的药物组合物及其应用
WO2022068918A1 (zh) 包含酸碱中和组合的药物组合物及其应用
CN112438942A (zh) 包含碱化剂及其协同物的药物组合物及其应用
CN101229131B (zh) 具有降低喜树碱类药物胃肠毒性的新型纳米微粒制剂
CN110870860A (zh) 包含氨基酸类营养素和常规无效化合物的药物组合物及其应用
CN110870858A (zh) 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用
CN104688676B (zh) 穿心莲内酯浓缩型液体组方及其医药用途
WO2021163897A1 (zh) 包含亚甲蓝类染料、营养素或/和常规抗肿瘤药的药物组合物及其应用
CN112439066A (zh) 包含化学消融剂和pH调节剂的药物组合物及其应用
CN110870918A (zh) 包含氨基酸类营养素和抗肿瘤化疗药物的药物组合物及其应用
CN107412172A (zh) 一种紫杉醇白蛋白纳米混悬剂冻干粉及其制备工艺
CN102526714B (zh) 治疗肿瘤的药物组合物及其制备方法
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
CN112891327A (zh) 瑞德西韦雾化吸入用液体制剂及其制备方法
CN108815128B (zh) 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法
CN107569686A (zh) 包含活体染料和金属化合物的药物组合物及其用途
CN100377712C (zh) 葫芦素脂质体组方及其制剂
BR112020006658A2 (pt) métodos de tratamento de infecções bacterianas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042096

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20210511

RJ01 Rejection of invention patent application after publication